{
    "clinical_study": {
        "@rank": "14822", 
        "arm_group": {
            "arm_group_label": "Canagliflozin (JNJ-28431754) + glyburide", 
            "arm_group_type": "Experimental", 
            "description": "Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine how multiple doses of canagliflozin (JNJ-28431754)\n      affect the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie,\n      how the drug affects the body) of a single dose of glyburide."
        }, 
        "brief_title": "A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2008", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This study will be an open-label (all volunteers and study staff know the identity of the\n      assigned treatment), single-center, fixed-sequence study (all volunteers receive the same\n      medication on the same days) to determine how canagliflozin (a drug currently being\n      investigated for the treatment of type 2 diabetes mellitus) affects the pharmacokinetics and\n      pharmacodynamics of glyburide (a blood glucose-lowering agent used to treat patients with\n      diabetes). The study will consist of 3 phases; a screening phase, an open-label treatment\n      phase, and an end-of-study (or follow-up) phase. During the open-label treatment phase, each\n      volunteer will receive a single 1.25 mg dose of glyburide on Day 1, followed by 200 mg\n      canagliflozin once daily on Days 4 through 8. On Day 9 volunteers will receive both\n      glyburide 1.25 mg and canagliflozin 200 mg. Each volunteer will participate in the study for\n      approximately 40 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Volunteer must have a body mass index (BMI = weight in kg/height in m2) between 18\n             and 30 kg/m2 (inclusive) and body weight not less than 50 kg        Exclusion\n             Criteria:\n\n          -  Volunteer has a history of or currently active illness considered to be clinically\n             significant by the Investigator or any other illness that the Investigator considers\n             should exclude the patient from the study or that could interfere with the\n             interpretation of the study results\n\n          -  Volunteer has a fasting plasma glucose < 100 mg/dL (as measured by oral glucose\n             tolerance test) and a 2-hour plasma glucose <= 140 mg/dL\n\n          -  History of smoking or use of nicotine-containing substances within the previous 6\n             months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733108", 
            "org_study_id": "CR014872", 
            "secondary_id": "28431754DIA1004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Canagliflozin (JNJ-28431754) + glyburide", 
                "description": "One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.", 
                "intervention_name": "Glyburide", 
                "intervention_type": "Drug", 
                "other_name": "Micronase"
            }, 
            {
                "arm_group_label": "Canagliflozin (JNJ-28431754) + glyburide", 
                "description": "One 200 mg tablet taken orally (by mouth) on Days 4 through 9.", 
                "intervention_name": "Canagliflozin (JNJ-28431754)", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-28431754"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glyburide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "Canagliflozin (JNJ-28431754)", 
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "Glyburide (MICRONASE)"
        ], 
        "lastchanged_date": "December 11, 2012", 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Drug-Drug Interaction Study in Healthy Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of Glyburide", 
        "overall_official": {
            "affiliation": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
            "last_name": "Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Comparison of plasma concentrations of glyburide following administration of a single dose of glyburide alone or in combination with multiple doses of canagliflozin (JNJ-28431754). This will be used to determine whether there is a pharmacokinetic interaction between glyburide and canagliflozin.", 
                "measure": "Plasma concentrations of glyburide", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 12"
            }, 
            {
                "description": "Comparison of plasma concentrations of glyburide metabolites following administration of a single dose of glyburide alone or in combination with multiple doses of canagliflozin (JNJ-28431754). This will be used to determine whether there is a pharmacokinetic interaction between glyburide and canagliflozin.", 
                "measure": "Plasma concentrations of glyburide metabolites", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733108"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Plasma glucose concentrations following the administration of a single dose of glyburide after the administration of multiple doses of canagliflozin (JNJ-28431754) will be used to determine whether there is a pharmacodynamic interaction (changes in plasma glucose) between glyburide and canagliflozin. The area under the plasma glucose concentration-time curve (AUC) will be used as the key pharmacodynamic parameter.", 
                "measure": "Change from baseline in plasma glucose concentrations", 
                "safety_issue": "No", 
                "time_frame": "Day -1 (Baseline) up to Day 9"
            }, 
            {
                "description": "Plasma insulin concentrations following the administration of a single dose of glyburide after the administration of multiple doses of canagliflozin (JNJ-28431754) will be used to determine whether there is a pharmacodynamic interaction (changes to plasma insulin) between glyburide and canagliflozin. The area under the plasma insulin concentration-time curve (AUC) will be used as the key pharmacodynamic parameter.", 
                "measure": "Change from baseline in plasma insulin concentrations", 
                "safety_issue": "No", 
                "time_frame": "Day -1 (Baseline) up to Day 9"
            }, 
            {
                "description": "Plasma C-peptide is formed during the body's production of insulin. Plasma C-peptide concentrations following the administration of a single dose of glyburide after the administration of multiple doses of canagliflozin (JNJ-28431754) will be used to determine whether there is a pharmacodynamic interaction (changes to plasma C-peptide) between glyburide and canaglifloxin. The area under the plasma C-peptide concentration-time curve (AUC) will be used as the key pharmacodynamic parameter.", 
                "measure": "Change from baseline in plasma C-peptide concentrations", 
                "safety_issue": "No", 
                "time_frame": "Day -1 (Baseline) up to Day 9"
            }
        ], 
        "source": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2008", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}